Two large cohorts (n=46 n=43) of patients with melanoma reported a median OS of 11.5 months (range 7-19), as well as 1-year, 2-year and 5-year OS rates of 36%, 26% and 13%, respectively, in patients that responded to IT IL-2 (87, 88). The gene discussed is IL2; the disease is melanoma.